Prurigo Nodularis In Practice: Exploring Treatment Decisions Through Patient Cases
Gil Yosipovitch, MD, discusses how prurigo nodularis represents one of the most severe itching conditions in dermatology and how recent advances in targeted biologic treatments like dupilumab and nemolizumab have revolutionized patient care by effectively breaking the itch-scratch cycle and dramatically improving quality of life for patients who previously had limited treatment options.
EP. 1: Exploring the Impact of Itch and Treatment Advances in Prurigo Nodularis
June 30th 2025An expert discusses how prurigo nodularis represents one of the most severe itching conditions in dermatology, significantly impacting patients' quality of life and sleep, and explains the importance of breaking the itch-scratch cycle while highlighting recent treatment advances with targeted biologics like dupilumab and nemolizumab.
EP. 2: Prioritizing Rapid Itch Relief in a 58-Year-Old Patient With Severe Prurigo Nodularis
July 29th 2025An expert discusses how to approach a 58-year-old African American woman with severe prurigo nodularis experiencing extreme itch (9/10 rating) and extensive lesions, emphasizing the need for rapid systemic intervention with nemolizumab due to its faster onset of itch relief compared with other biologics.
EP. 4: Focusing on Treatment Adherence and Safety in a 68-Year-Old Patient With Prurigo Nodularis
July 29th 2025An expert discusses how to approach treatment selection in a 68-year-old Latino patient with multiple comorbidities, including chronic kidney disease, emphasizing the importance of considering injection frequency preferences, treatment burden, and the excellent safety profile of targeted biologics in older patients with complex medical histories.
